{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-116023","form_type":"8-K","ticker":"MTVA","cik":"0001638287","company_name":"MetaVia Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.526557+00:00","generated_at":"2026-06-22T03:48:46.718030+00:00","sec_items":["1.01","3.02","3.03","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"NeuroBo closes $32.3M financing and licenses NASH/obesity drugs from Dong-A","bullets":["Public offering grossed ~$17.3M (full over-allotment); private placement $15M from Dong-A; net proceeds ~$15.1M.","Exclusive license for DA-1241 (NASH) and DA-1726 (obesity/T2D); NeuroBo holds global rights ex-Asia Pacific.","Issued 3.1M common shares, 2.6M Series B preferred shares, and warrants for up to 11.5M common shares.","Warrants exercisable at $3.00 after stockholder approval; meeting expected by Dec 22, 2022.","Preferred stock has no dividend rights, no liquidation preference, and limited voting rights."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-116023","json":"https://secwatch.observer/filing/0001104659-22-116023.json","markdown":"https://secwatch.observer/filing/0001104659-22-116023.md","text":"https://secwatch.observer/filing/0001104659-22-116023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638287/000110465922116023/0001104659-22-116023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638287/000110465922116023/tm2225873d12_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:48:46.718030+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"98c61c0a3e2fbb65c21086603f9e9894b97fb627","claim":"MetaVia Inc.: Filed Certificate of Designations for Series A and Series B Convertible Preferred Stock (effective 2022-11-04).","evidence_excerpt":"On November 4, 2022, the Company filed the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the “ Series A Certificate of Designations ”) and the Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (the “ Series B Certificate of Designations ,” and together with the Series A Certificate of Designations, the “ Certificate of Designations ”) with the Secretary of State of the State of Delaware.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638287/000110465922116023/0001104659-22-116023-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2022-11-04"}],"fact_type":"governance_change"},{"claim_id":"0e9cde8d0f60ead0e7dab2763a60360639b97d0e","claim":"MetaVia Inc. entered into Underwriting Agreement with Ladenburg Thalmann & Co. Inc. valued at net proceeds approximately $15.1 million (effective 2022-11-04).","evidence_excerpt":"On November 4, 2022, NeuroBo Pharmaceuticals, Inc. (the “ Company ”) entered into an Underwriting Agreement (the “ Underwriting Agreement ”) with Ladenburg Thalmann & Co. Inc. (the “ Underwriter ”), pursuant to which the Company issued and sold, in an underwritten public offering by the Company (the “ Public Offering ”), (a) 2,397,003 Class A Units (the “ Class A Units ”), with each Class A Unit consisting of (i) one share of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), (ii) one warrant to purchase one share of Common Stock exercisable following approval of the Company’s stockholders (each, a “ Series A Warrant ”) and (iii) one warrant to purchase one share of Common Stock exercisable following approval of the Company’s stockholders (each, a “ Series B Warrant ,” and together with the Class A Series A Warrants, the “ Warrants ”), with each Class A Unit offered to the public at an offering price of $3.00 per Class A Unit and (b) 2,602,997 Class B Units","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638287/000110465922116023/0001104659-22-116023-index.htm","confidence":0.98,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Ladenburg Thalmann & Co. Inc."},{"label":"Value","value":"net proceeds approximately $15.1 million"},{"label":"Effective","value":"2022-11-04"}],"fact_type":"material_agreement"},{"claim_id":"e7ff6191f0024d27ae4315ab6cab4cdc74ec037f","claim":"MetaVia Inc. entered into Warrant Agency Agreement with American Stock Transfer & Trust Company LLC valued at governs warrants sold in Public Offering (effective 2022-11-08).","evidence_excerpt":"On November 8, 2022, the Company also entered into a warrant agency agreement with the Company’s transfer agent, American Stock Transfer & Trust Company LLC, who will act as warrant agent for the Company, setting forth the terms and conditions of the Warrants sold in the Public Offering (the “ Warrant Agency Agreement ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638287/000110465922116023/0001104659-22-116023-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"American Stock Transfer & Trust Company LLC"},{"label":"Value","value":"governs warrants sold in Public Offering"},{"label":"Effective","value":"2022-11-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}